SCHEMBL2996053

SCHEMBL2996053

CC1=C(C(=O)OC(c2ccc(F)cc2)c2ccc(F)cc2)C(c2cccs2)n2nnnc2N1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.69
HPGD P15428 4/20 0.69
HTT P42858 3/20 0.69
NPSR1 Q6W5P4 3/20 0.60
LMNA P02545 2/20 0.60
MAPT P10636 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
GAA P10253 1/20 0.54
ADORA2B P29275 6/20 0.52
TSHR P16473 1/20 0.51
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269150 0.82 ALDH1A1 (1.00) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3250065 0.81 ALDH1A1 (0.53) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3003790 0.73 ALDH1A1 (0.66) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL2996052 0.70 ALDH1A1 (0.63) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3005222 0.70 ALDH1A1 (0.50) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3005227 0.70 ALDH1A1 (0.50) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL2999694 0.70 ALDH1A1 (0.59) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3000271 0.67 ALDH1A1 (0.54) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL3002666 0.67 ALDH1A1 (0.69) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL10376255 0.66 MEN1 (0.80) ALDH1A1HPGDHTTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 ALDH1A1 1229/4885HPGD 262/4885HTT 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.